Vascular Endothelial Growth Factor Receptor Articles & Analysis
4 news found
About FOTIVDA® (tivozanib) FOTIVDA® (tivozanib) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). ...
(“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate ...
Data highlighting outcomes of the subgroup of TIVO-3 patients who received tivozanib following prior axitinib therapy suggests that tivozanib, a potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), is more active following prior VEGFR TKI therapy than ...
-SITC 2021, re-hosted face to face meeting for the first time in 2 years due to COVID-19…topic for overcoming tolerance of Immuno-oncology -International researchers pay attention to immuno-oncology GI-101’s material excellence that had the mechanism of overcoming tolerance GI Innovation revealed KEYNOTE-B59’s clinical research process of GI-101(CD80/IL-2 variant bispecific ...